1,633
Views
50
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

, , , , , , , , , , , , , , , , , , , , , , & show all
Pages 3320-3328 | Received 03 Nov 2014, Accepted 10 Mar 2015, Published online: 15 May 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Foteini Theodorakakou, Meletios A. Dimopoulos & Efstathios Kastritis. (2021) Mutation-dependent treatment approaches for patients with complex multiple myeloma. Expert Review of Precision Medicine and Drug Development 6:3, pages 189-201.
Read now
Chenxing Du, Xuehan Mao, Yan Xu, Yuting Yan, Chenglu Yuan, Xin Du, Jiahui Liu, Huishou Fan, Qi Wang, Weiwei Sui, Shuhui Deng, Mingwei Fu, Zengjun Li, Chengwen Li, Jiawei Zhao, Shuhua Yi, Lanting Liu, Mu Hao, Dehui Zou, Yaozhong Zhao, Lugui Qiu & Gang An. (2020) 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib. Leukemia & Lymphoma 61:5, pages 1201-1210.
Read now
Judith Lind, Felix Czernilofsky, Sonia Vallet & Klaus Podar. (2019) Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs 24:3, pages 133-152.
Read now
Nicolas Kint, Sophie Vlayen & Michel Delforge. (2019) The treatment of multiple myeloma in an era of precision medicine. Expert Review of Precision Medicine and Drug Development 4:3, pages 153-162.
Read now
Jonas Lange, Georg Lenz & Birgit Burkhardt. (2017) Mature aggressive B-cell lymphoma across age groups – molecular advances and therapeutic implications. Expert Review of Hematology 10:2, pages 123-135.
Read now

Articles from other publishers (45)

Kazuhito Suzuki & Shingo Yano. (2023) IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?. Life 13:11, pages 2229.
Crossref
Yu-jia Xu, Kun Zeng, Ying Ren, Chen-yu Mao, Ying-hui Ye, Xiao-ting Zhu, Zi-ying Sun, Bi-yin Cao, Zu-bin Zhang, Guo-qiang Xu, Zhen-qian Huang & Xin-liang Mao. (2023) Inhibition of USP10 induces myeloma cell apoptosis by promoting cyclin D3 degradation. Acta Pharmacologica Sinica.
Crossref
Zhen Liu, Youqiong Ye, Yizhe Liu, Yanfang Liu, Huifang Chen, Mengting Shen, Zhen Wang, Shenglin Huang, Leng Han, Zhiao Chen & Xianghuo He. (2022) RNA Helicase DHX37 Facilitates Liver Cancer Progression by Cooperating with PLRG1 to Drive Superenhancer-Mediated Transcription of Cyclin D1. Cancer Research 82:10, pages 1937-1952.
Crossref
Yuen Lam Dora Ng, Evelyn Ramberger, Stephan R. Bohl, Anna Dolnik, Christian Steinebach, Theresia Conrad, Sina Müller, Oliver Popp, Miriam Kull, Mohamed Haji, Michael Gütschow, Hartmut Döhner, Wolfgang Walther, Ulrich Keller, Lars Bullinger, Philipp Mertins & Jan Krönke. (2022) Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nature Communications 13:1.
Crossref
Darren Pan & Joshua Richter. (2022) Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Frontiers in Oncology 11.
Crossref
Ruixue Huang & Ping-Kun Zhou. (2021) DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduction and Targeted Therapy 6:1.
Crossref
Ming He, Wenxing Lv & Yu Rao. (2021) Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation. Frontiers in Cell and Developmental Biology 9.
Crossref
Alessandra Dall’Acqua, Michele Bartoletti, Nastaran Masoudi-Khoram, Roberto Sorio, Fabio Puglisi, Barbara Belletti & Gustavo Baldassarre. (2021) Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. Cancers 13:12, pages 3035.
Crossref
Yanping Hu, Yujin Wang, Na Li, Li Chen & Jianbo Sun. (2021) Discovery of novel dihydroartemisinin-cinnamic hybrids inducing lung cancer cells apoptosis via inhibition of Akt/Bad signal pathway. Bioorganic Chemistry 111, pages 104903.
Crossref
Anna Richter, Nina Schoenwaelder, Sina Sender, Christian Junghanss & Claudia Maletzki. (2021) Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches. Cancers 13:10, pages 2497.
Crossref
Min Zhao, Min Hu, Yong Chen, Heyi Liu, Yulu Chen, Bin Liu & Baijun Fang. (2021) Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma. Biochemical and Biophysical Research Communications 549, pages 150-156.
Crossref
Tina Paradzik, Cecilia Bandini, Elisabetta Mereu, Maria Labrador, Elisa Taiana, Nicola Amodio, Antonino Neri & Roberto Piva. (2021) The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma. Cancers 13:6, pages 1235.
Crossref
Ignacio J. Cardona-Benavides, Cristina de Ramón & Norma C. Gutiérrez. (2021) Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells 10:2, pages 336.
Crossref
Marika A. V. Reinius & Elizabeth Smyth. (2021) Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges. Expert Reviews in Molecular Medicine 23.
Crossref
Kai Yuan, Xiao Wang, Haojie Dong, Wenjian Min, Haiping Hao & Peng Yang. (2021) Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharmaceutica Sinica B 11:1, pages 30-54.
Crossref
Qi Du, Xiang Guo, Miao Wang, Yongfu Li, Xiaoyi Sun & Qin Li. (2020) The application and prospect of CDK4/6 inhibitors in malignant solid tumors. Journal of Hematology & Oncology 13:1.
Crossref
Ashwani K. Sood, Michael Nemeth, Jianmin Wang, Yun Wu & Shipra Gandhi. (2020) Opportunities for Antigen Discovery in Metastatic Breast Cancer. Frontiers in Immunology 11.
Crossref
Yong Wang, Shouzhen Chen, Shuna Sun, Guangyi Liu, Lipeng Chen, Yangyang Xia, Jianfeng Cui, Wenfu Wang, Xuewen Jiang, Lei Zhang, Yaofeng Zhu, Yongxin Zou & Benkang Shi. (2020) Wogonin Induces Apoptosis and Reverses Sunitinib Resistance of Renal Cell Carcinoma Cells via Inhibiting CDK4-RB Pathway. Frontiers in Pharmacology 11.
Crossref
Jin Shi, Shigang Lv, Miaojing Wu, Xianggan Wang, Yan Deng, Yansheng Li, Kuanxun Li, Hongyu Zhao, Xingen Zhu & Minhua Ye. (2020) HOTAIR‐EZH2 inhibitor AC1Q3QWB upregulates CWF19L1 and enhances cell cycle inhibition of CDK4/6 inhibitor palbociclib in glioma. Clinical and Translational Medicine 10:1, pages 182-198.
Crossref
Claire Gourzones, Caroline Bret & Jerome Moreaux. (2019) Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma. Frontiers in Genetics 10.
Crossref
Shang Su, Zimo Yang, Hongying Gao, Haiyan Yang, Songbiao Zhu, Zixuan An, Juanjuan Wang, Qing Li, Sarat Chandarlapaty, Haiteng Deng, Wei Wu & Yu Rao. (2019) Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. Journal of Medicinal Chemistry 62:16, pages 7575-7582.
Crossref
Jennypher Mudunuru, Chen Ren, David R. Taft & Manoj Maniar. (2019) Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats. European Journal of Drug Metabolism and Pharmacokinetics 44:4, pages 531-538.
Crossref
Antonio Giovanni Solimando, Matteo Claudio Da Vià, Sebastiano Cicco, Patrizia Leone, Giuseppe Di Lernia, Donato Giannico, Vanessa Desantis, Maria Antonia Frassanito, Arcangelo Morizio, Julia Delgado Tascon, Assunta Melaccio, Ilaria Saltarella, Giuseppe Ranieri, Roberto Ria, Leo Rasche, K. Martin Kortüm, Andreas Beilhack, Vito Racanelli, Angelo Vacca & Hermann Einsele. (2019) High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. Journal of Clinical Medicine 8:7, pages 997.
Crossref
Faiz Anwer, Kevin Mathew Gee, Ahmad Iftikhar, Mirza Baig, Atlantis Dawn Russ, Sabina Saeed, Muhammad Abu Zar, Faryal Razzaq, Jennifer Carew, Steffan Nawrocki, Hussam Al-Kateb, Nadia Nunes Cavalcante Parr, Ali McBride, Jason Valent & Christy Samaras. (2019) Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 19:7, pages 397-405.
Crossref
Maria Pia Abruzzese, Maria Teresa Bilotta, Cinzia Fionda, Alessandra Zingoni, Alessandra Soriani, Maria Teresa Petrucci, Maria Rosaria Ricciardi, Rosa Molfetta, Rossella Paolini, Angela Santoni & Marco Cippitelli. (2019) The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors. Cell Death & Disease 10:4.
Crossref
Małgorzata Kubczak, Aleksandra Szustka, Jerzy Błoński, Tomaš Guck�, Małgorzata Misiewicz, Vladmir Krystof, Paweł Robak & Małgorzata Rogalińska. (2019) Dose and drug changes in chronic lymphocytic leukemia cell response in�vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors. Molecular Medicine Reports.
Crossref
Michael J. Böhm, Ralf Marienfeld, Daniela Jäger, Kevin Mellert, Adrian von Witzleben, Silke Brüderlein, Mathias Wittau, Alexandra von Baer, Markus Schultheiss, Regine Mayer-Steinacker, Frank G. Rücker, Peter Möller, Lars Bullinger & Thomas F. E. Barth. (2019) Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib. Sarcoma 2019, pages 1-10.
Crossref
Tamojit Chaudhuri, K Govind Babu, KC Lakshmaiah, Lokanatha Dasappa, Linu Abraham Jacob, MC Suresh Babu, AH Rudresha, KN Lokesh & LK Rajeev. (2021) Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer. Indian Journal of Medical and Paediatric Oncology 40:01, pages 15-20.
Crossref
S Parylo, A Vennepureddy, V Dhar, P Patibandla & A Sokoloff. (2018) Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment. Journal of Oncology Pharmacy Practice 25:1, pages 110-129.
Crossref
Benoît Tessoulin, Agnès Moreau-Aubry, Géraldine Descamps, Patricia Gomez-Bougie, Sophie Maïga, Alban Gaignard, David Chiron, Emmanuelle Ménoret, Steven Le Gouill, Philippe Moreau, Martine Amiot & Catherine Pellat-Deceunynck. (2018) Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. Journal of Hematology & Oncology 11:1.
Crossref
Chunyan Gu, Xuefang Jing, Carol Holman, Ramakrishna Sompallae, Fenghuang Zhan, Guido Tricot, Ye Yang & Siegfried Janz. (2018) Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer 18:1.
Crossref
Hanley N. Abramson. (2018) The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets. Clinical Lymphoma Myeloma and Leukemia 18:9, pages 611-627.
Crossref
Chunyan Gu, Carol Holman, Ramakrishna Sompallae, Xuefang Jing, Michael Tomasson, Dirk Hose, Anja Seckinger, Fenghuang Zhan, Guido Tricot, Hartmut Goldschmidt, Ye Yang & Siegfried Janz. (2018) Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer Journal 8:2.
Crossref
Carmela Coppola, Anna Rienzo, Giovanna Piscopo, Antonio Barbieri, Claudio Arra & Nicola Maurea. (2018) Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treatment Reviews 63, pages 135-143.
Crossref
Smruthi Vijayaraghavan, Stacy Moulder, Khandan Keyomarsi & Rachel M. Layman. (2017) Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Targeted Oncology 13:1, pages 21-38.
Crossref
Christopher C. Mills, EA. Kolb & Valerie B. Sampson. (2018) Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy. Cancer Research 78:2, pages 320-325.
Crossref
Marcus Schmidt & Martin Sebastian. 2018. Small Molecules in Oncology. Small Molecules in Oncology 153 175 .
Scott Ely, Peter Forsberg, Ihsane Ouansafi, Adriana Rossi, Alvin Modin, Roger Pearse, Karen Pekle, Arthur Perry, Morton Coleman, David Jayabalan, Maurizio Di Liberto, Selina Chen-Kiang, Ruben Niesvizky & Tomer M. Mark. (2017) Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical Lymphoma Myeloma and Leukemia 17:12, pages 825-833.
Crossref
Verónica González-Calle, Niamh Keane, Esteban Braggio & Rafael Fonseca. (2017) Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. Clinical Lymphoma Myeloma and Leukemia 17:10, pages 621-630.
Crossref
Matthew InghamGary K. Schwartz. (2017) Cell-Cycle Therapeutics Come of Age. Journal of Clinical Oncology 35:25, pages 2949-2959.
Crossref
Kerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, Paul J Christos, John J Wright, George Raptis, Gang Han, Miguel Villalona-Calero, Cynthia X Ma, Dawn Hershman, Joseph Baar, Paula Klein, Tessa Cigler, G Thomas Budd, Yelena Novik, Antoinette R Tan, Susan Tannenbaum, Anupama Goel, Ellis Levine, Charles L Shapiro, Eleni Andreopoulou, Michael Naughton, Kevin Kalinsky, Sam Waxman & Doris Germain. (2016) Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. npj Breast Cancer 2:1.
Crossref
Ben O'Leary, Richard S. Finn & Nicholas C. Turner. (2016) Treating cancer with selective CDK4/6 inhibitors. Nature Reviews Clinical Oncology 13:7, pages 417-430.
Crossref
C Gu, Y Yang, R Sompallae, H Xu, V S Tompkins, C Holman, D Hose, H Goldschmidt, G Tricot, F Zhan & S Janz. (2015) FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia 30:4, pages 873-882.
Crossref
Deepak Perumal, Pei-Yu Kuo, Violetta V. Leshchenko, Zewei Jiang, Sai Krishna Athaluri Divakar, Hearn Jay Cho, Ajai Chari, Joshua Brody, M.V. Ramana Reddy, Weijia Zhang, E. Premkumar Reddy, Sundar Jagannath & Samir Parekh. (2016) Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Research 76:5, pages 1225-1236.
Crossref
Mark C. de Gooijer, Ping Zhang, Nishita Thota, Isabel Mayayo-Peralta, Levi C. M. Buil, Jos H. Beijnen & Olaf van Tellingen. (2015) P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Investigational New Drugs 33:5, pages 1012-1019.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.